Mohamed Derbala, MD

Sr. Research Scientist, MD Anderson Cancer Center. Tweets are mine.

[Mohamed Derbala, MD @MDerbalaMD]

Excited to share our latest editorial in @JAMAOnc, https://t.co/HNlfS0wkPV. As one of the authors, I'm thrilled to explore the forefront of cancer treatment, its promises, and the hurdles we face. @HajjarJoud, @ANaingMD, @PatrickHwuMD, @Dr_R_Kurzrock, @MDAndersonNews, @OncoAlert

[Abraham Naing @AbrahamNaing]

Great to be in Chicago with Yulu Liu, a fellow member of the Youth Entrepreneurs Club of Greater Houston, and Dr. Yali Yang.

Yulu and I are grateful for opportunities to learn from physicians, researchers, and advocates who are working to improve the lives of patients through research and innovation.

The Youth Entrepreneurs Club of Greater Houston is part of the Youth Initiative Program of Khin Naing Foundation USA @khinnaingUSA and is supported by Junior Achievement of South Texas. Experiences like this highlight the value of youth engagement, mentorship, and creating opportunities for students to explore healthcare and research.

Thank you, Dr. Yang, for your continued support and encouragement.

[JIPO Editors @JIPOEditors]

CLOSING TOMORROW! The #JIPO Editorial Fellowship is open from now through June 2nd. Apply before the deadline closes: https://t.co/07TdqRgJ5H @InnoJournals #fellowship #medicalpublishing #peerreview @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @FawazOumaya @OncologyNetwork

[UT MD Anderson @UTMDAnderson]

Presented by Dr. Neal Akhave at #ASCO26, a phase II study is evaluating ivonescimab for patients with advanced cutaneous squamous cell carcinoma whose disease has progressed on prior immunotherapy.

The trial aims to expand treatment options for patients with limited alternatives. @NealAkhave @ANaingMD #EndCancer 3/7

[UT MD Anderson @UTMDAnderson]

Antibody-drug conjugates and other novel therapies are expanding treatment possibilities for patients with endometrial cancer.

At #ASCO26, Dr. Funda Meric-Bernstam discussed emerging strategies to overcome treatment resistance and highlighted how new targeted approaches may help improve outcomes for patients with advanced disease. #EndCancer

[UT MD Anderson @UTMDAnderson]

In a Phase 2 study of people with rare cancers, researchers found that certain features of the tumor microenvironment may serve as predictive markers of response beyond what can currently be provided: https://t.co/JSr4bIQ9Xv @anaingmd #EndCancer

[Mohamed Derbala, MD @MDerbalaMD]

Now accruing at @UTMDAnderson: Phase 1 trial of SAR445877, an immunocytokine, in combination with FOLFOX + bevacizumab for 1st line Tx of MSS mCRC. https://t.co/rW9UYzlyaS
PIs: Aung Naing @AnaingMD and Pia Morelli @PiaMorelli9
Patient/physician referrals: 713-562-1930
NCT07500298

[JIPO Editors @JIPOEditors]

Brand new #JIPO review by Low et al. explores "CIITA: A Master MHC-II Regulator Impacting Cancer and Beyond" https://t.co/Z7qKlVwojS #CIITA #MHCII #immunoregulatory @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @FawazOumaya @OncologyNetwork

[JIPO Editors @JIPOEditors]

May is National Melanoma and Skin Cancer Detection and Prevention Month. At #JIPO we're dedicated to #ExposetheTruth on these cancers that affect so many. Learn more and participate at https://t.co/wNzQTvtVt9 #SkinCancerPreventionMonth #MelanomaPreventionMonth

[JIPO Editors @JIPOEditors]

Didn't get a chance to attend this year's Immunotherapy & Precision Oncology Forum #IPOF2026? Read the accepted abstracts in #JIPO: https://t.co/gA7kw5jJcs @AnaingMD @arjazieh @innovativehci @jibranahmed1 @mderbalamd @DoubaZain @FawazOumaya @OncologyNetwork #precisiononcology #cancercare

[JIPO Editors @JIPOEditors]

Research article at #JIPO: Shaya et al. explore circulating tumor DNA as a prognostic biomarker for selecting participants in early phase clinical trials. https://t.co/Igqs8uaAFX #clinicaltrials #biomarker @SammyShaya @OncologyNetwork

[Khin Naing Foundation USA @KhinNaingUSA]

Colorectal cancer is rising in younger adults. Don’t miss this important webinar from Khin Naing Foundation USA featuring Dr. Scott Kopetz @skopetz @MDAndersonnews , a nationally recognized expert in colorectal cancer: “Understanding Colorectal Cancer: Awareness, Risk, and Early Action.” @OncoAlert @gillmorgan

May 2, 2026 | 2:00 PM CT | 7:00 PM GMT | Zoom
Free to attend; registration is required. Live Q&A included.
Register: https://t.co/lbv5pJ9Vqj

[JIPO Editors @JIPOEditors]

#JIPO Editor in Chief and Managing Editor meet up in person!
#IPOF2026 @ANaingMD @EditorValerie @InnoJournals @Innovativehci

[Mohamed Derbala, MD @MDerbalaMD]

Really enjoyed Dr. @ANaingMD ’s presentation at #IPOF2026 on ICIs and irAEs. Excellent talk on an important and evolving topic in immunotherapy. @OncologyNetwork @JIPOEditors @InnoJournals @DoubaZeina @BettzyStephen

[JIPO Editors @JIPOEditors]

THIS WEEKEND: #IPOF2026 takes place Saturday; there's still time to register, in-person or virtually! You won't want to miss our exceptional speakers & crucial updates on #precisiononcology https://t.co/OBgLksrodL @OncologyNetwork @LowellAnthony @MatthewKurianMD @AnaingMD

[JIPO Editors @JIPOEditors]

New #JIPO case study by Disel et al. explores "Lessons from Exceptional Responders w High-Grade Brain Tumors Treated w Precision Targeted Therapies
https://t.co/RAGVohMUwE #glioma #precisiononcology #targetedtherapy @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @OncologyNetwork

[Mohamed Derbala, MD @MDerbalaMD]

Cutaneous irAEs after ICIs can look a lot like autoimmune skin disease. This study https://t.co/KFeMzK2D5q highlights just how heterogeneous they are, with THY1 upregulation & M2 macrophages standing out as possible players @AnaingMD @HajjarJoud @cara_haymaker @kchenken @NejlaL08

[Mohamed Derbala, MD @MDerbalaMD]

@mjmoussa_ @OncHahn @JCOPO_ASCO @DocMattCampbell @OAlhalabiMD @UTMDAnderson @andreevdrakhlin @AVenkatesanMD @PavlosMsaouel @BladderCancerUS @SGoswamiMDPhD @IMG_Oncologists @johnlin08 Congratulations Mohammad!! Well done!

[Mohamed Derbala, MD @MDerbalaMD]

An interesting read!

[JIPO Editors @JIPOEditors]

Watson et al. examine the pairing of targeted agents with immunotherapies to treat advanced and metastatic sarcomas. https://t.co/EgzkX48Nf6 #sarcoma #JIPO @ANaingMD @jibranahmed1 @mderbalamd @DoubaZain @FawazOumaya @OncologyNetwork

[JIPO Editors @JIPOEditors]

Excited to have Dr. Lowell Anthony joining us at #IPOF2026 on April 11th with a NET Management Update!

Meeting website & registration: https://t.co/HL22nRb2Fg

#precisiononcology #CincinnatiOH #JIPO #medconference

@OncologyNetwork
@LowellAnthony

[JIPO Editors @JIPOEditors]

Join us April 11th for #IPOF2026, where Dr. James Maher will deliver an update on genitourinary oncology. Don't miss this 1 day event, packed with insights.

Meeting website & registration: https://t.co/HL22nRbAuO

#precisiononcology #JIPO #medconference

@OncologyNetwork